Evidence map›Paper›PMID 34930979›Full record

Trial reportScientific reports2021

The randomized clinical trial results of the anxiety treatment in patients with somatoform dysfunction and neurotic disorders.

Vladimir Anatolevich Parfenov, Pavel Rudolfovich Kamchatnov, Dina Rustemovna Khasanova, Enver Ibragimovich Bogdanov, Tatiana Markovna Lokshtanova, Aleksandr Vitalevich Amelin, Natalya Nikolaevna Maslova, Nataliia Vyacheslavovna Pizova, Galina Nikolaevna Belskaya, Evgeny Robertovich Barantsevich and 4 more

RetractedOpen access · goldAbstract readMulticenter StudyRandomized Controlled TrialRetracted Publication
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Neurological Signs of Postcovid Syndrome.Neuroscience and behavioral physiology · 2022
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 11 institutions in 2 countries.

Vladimir Anatolevich ParfenovI.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
Pavel Rudolfovich KamchatnovPirogov Russian National Research Medical University, Moscow, Russia.
Dina Rustemovna KhasanovaKazan State Medical University, Kazan, Russia.
Enver Ibragimovich BogdanovKazan State Medical University, Kazan, Russia.
Tatiana Markovna LokshtanovaPirogov Samara City Clinical Hospital №1, Samara, Russia.
Aleksandr Vitalevich AmelinPavlov Medical University, Saint Petersburg, Russia.
Natalya Nikolaevna MaslovaSmolensk State Medical University, Smolensk, Russia.
Nataliia Vyacheslavovna PizovaClinical Hospital №8, Yaroslavl, Russia.
Galina Nikolaevna BelskayaResearch Center of Neurology, Moscow, Russia.
Evgeny Robertovich BarantsevichPavlov Medical University, Saint Petersburg, Russia.
Gulsum Abdurahmanovna DuchshanovaKhoja Akhmet Yassawi International Kazakh-Turkish University, Turkestan, Kazakhstan.
Saltanat Ualihanovna KamenovaDepartment of Medicine, Al-Farabi Kazakh National University, Almaty, Kazakhstan.
Oleg Vladimirovich KolokolovRazumovsky State Medical University, Saratov, Russia.
Alexey Borisovich GlazunovPirogov Medical University, Moscow, Russia. alexeyglazunov@yandex.ru.
First Pavlov State Medical University of St. Petersburg · RUKazan State Medical University · RUPirogov Russian National Research Medical University · RUAhmet Yesevi University · KZAl-Farabi Kazakh National University · KZClinical Hospital No. 8 · RUResearch Center of Neurology · RUSamara City N.I. Pirogov Clinical Hospital №1 · RUSaratov State Medical University · RUSechenov University · RUSmolensk State Medical University · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The existing treatments for somatoform dysfunction (SfD), reaction to severe stress (RSS), and adjustment disorders (AjD) are insufficiently effective and safe. Anxiolytic drug Tenoten proved effective in clinical trials (CT). The aim of this multicenter double-blind placebo-controlled randomized CT was to investigate the safety and efficacy of Tenoten in the treatment of anxiety in adults with SfD, RSS, AjD and other neurotic disorders (oNDs). 390 adult patients with SfD, RSS and AjD or oNDs with the Hospital Anxiety and Depression scale-anxiety (HADS-A) score ≥ 11 were randomized into 4 groups (n = 127 in Tenoten group 1 (4 tablets/day); n = 131 in Tenoten group 3 (8 tablets/day), n = 132 in combined Placebo group 2 + 4). The changes from baseline in the mean Hamilton Anxiety Rating Scale (HAM-A) score in groups 1 and 3 after 12 weeks were the primary outcome. The decrease of the HAM-A score from 18.81 ± 5.81 to 7.26 ± 4.63 (in group 1) and from 18.38 ± 4.3 to 6.40 ± 4.02 (in group 3) was observed post-treatment (p

Indexed as

AdolescentAdultAnti-Anxiety AgentsAntibodiesAnxietyDouble-Blind MethodFemaleHumansMaleMiddle AgedNeurotic DisordersPatient SafetyPlacebosPsychiatric Status Rating ScalesSeverity of Illness IndexSomatoform DisordersAnti-Anxiety AgentsAntibodiesPlacebostenoten

Identifiers

PMID34930979
PMCPMC8688518
OpenAlexW4200370797

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.